Clinical Trial Update: Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis [Phase 4]

View source ↗

Summary

Phase 4 trial update presents immunogenetic profiling data for dupilumab in atopic dermatitis. Results of the biomarker analyses have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: University of California, San Francisco | Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 4 | Status: COMPLETED | Results posted: 2025-11-14